All the news articles and press releases in one place.

Date / Time Source Ticker Company Sector Market Cap Announcement
14Jul16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
13Jul16 20:42 GNW 0QLR:LON Novartis AG Health 208,186m Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases
07Jul16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product
29Jun16 22:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM)
29Jun16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Largest global psoriasis survey shows 84% of people face discrimination and humiliation because of their skin
28Jun16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor
22Jun16 16:30 GNW 0QLR:LON Novartis AG Health 208,186m Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology
15Jun16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment
10Jun16 07:31 GNW 0QLR:LON Novartis AG Health 208,186m Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorder
10Jun16 07:30 GNW 0QLR:LON Novartis AG Health 208,186m Novartis presents data showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV)
09Jun16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m New data demonstrates Sandoz' etanercept and rituximab biosimilar candidates bioequivalent to originator products
08Jun16 21:30 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces AMG 334 significantly reduces patients' monthly migraine days in phase II study of chronic migraine prevention
08Jun16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016
06Jun16 19:39 GNW 0QLR:LON Novartis AG Health 208,186m Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma
06Jun16 15:53 GNW 0QLR:LON Novartis AG Health 208,186m Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer
04Jun16 21:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna®
02Jun16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis drug Afinitor® receives EU approval to treat certain types of advanced gastrointestinal (GI) and lung neuroendocrine tumors (NET)
25May16 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event
24May16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency
21May16 01:01 GNW 0QLR:LON Novartis AG Health 208,186m Novartis' Entresto® given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals
19May16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces investment in FortiHFy clinical program of Entresto® and heart failure
18May16 22:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting
18May16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer
17May16 16:30 GNW 0QLR:LON Novartis AG Health 208,186m Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis
17May16 16:30 GNW 0QLR:LON Novartis AG Health 208,186m Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis
17May16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis Foundation and partners launch innovative hypertension program in Vietnam
15May16 18:45 GNW 0QLR:LON Novartis AG Health 208,186m Major study published in NEJM confirms Novartis' Ultibro® Breezhaler® superiority over Seretide® in preventing COPD exacerbations
29Apr16 12:37 GNW 0QLR:LON Novartis AG Health 208,186m Novartis drug Afinitor® recommended by CHMP for European Union approval to treat select GI and lung neuroendocrine tumors
28Apr16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis celebrates 20th annual Community Partnership Day with more than 27,500 associates volunteering in their local communities
27Apr16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes
20Apr16 17:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis drug Afinitor® significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex
08Apr16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit's® nephrology indication
07Apr16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year and above with chronic ITP
02Apr16 16:00 GNW 0QLR:LON Novartis AG Health 208,186m New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless...
31Mar16 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis publishes updated 2015 segment financials reflecting new division structure
05Mar16 17:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis' Cosentyx superior to Stelara in delivering long-lasting skin clearance (PASI 90) for psoriasis patients at 52 weeks
26Feb16 19:44 GNW 0QLR:LON Novartis AG Health 208,186m FDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET)
23Feb16 12:20 GNW 0QLR:LON Novartis AG Health 208,186m Novartis shareholders approve all resolutions proposed by Board of Directors
19Feb16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)
18Feb16 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.
12Feb16 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer's biosimilar infliximab in EEA
11Feb16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
31Jan16 06:30 GNW 0QLR:LON Novartis AG Health 208,186m Novartis Foundation commemorates World Leprosy Day with its continued efforts to go the last mile toward elimination
27Jan16 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations
27Jan16 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations
17Jan16 21:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US
15Jan16 22:27 GNW 0QLR:LON Novartis AG Health 208,186m Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US
11Jan16 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis continues to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface Oncology
05Jan16 22:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPD
23Dec15 22:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patients
09Dec15 06:15 GNW 0QLR:LON Novartis AG Health 208,186m 300 million child-friendly antimalarial treatments supplied without profit by Novartis
08Dec15 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Sandoz advances its biosimilars program with European Medicines Agency (EMA) acceptance of regulatory submission for biosimilar etanercept
07Dec15 19:45 GNW 0QLR:LON Novartis AG Health 208,186m Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL
07Dec15 15:45 GNW 0QLR:LON Novartis AG Health 208,186m Phase III data shows Sandoz' proposed biosimilar pegfilgrastim has similar safety and efficacy as the reference product
06Dec15 16:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations
06Dec15 12:30 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma
05Dec15 14:30 GNW 0QLR:LON Novartis AG Health 208,186m Novartis announces Phase III studies of Jakavi show disease improvement in patients with myelofibrosis and polycythemia vera
02Dec15 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis presents new data on targeted combination therapy at SABCS reinforcing commitment to breast cancer patients
30Nov15 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis highlights clinical advances at ASH 2015, underscoring leadership in hematology research
24Nov15 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis' heart failure medicine Entresto(TM) receives EU approval
23Nov15 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis receives two landmark European approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis
18Nov15 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA
17Nov15 06:15 GNW 0QLR:LON Novartis AG Health 208,186m FLAME study shows superiority of Novartis' Ultibro® Breezhaler® over Seretide® in reducing COPD exacerbations
15Nov15 17:00 GNW 0QLR:LON Novartis AG Health 208,186m Alcon introduces Contoura Vision as first personalized LASIK procedure at American Academy of Ophthalmology Annual Meeting
08Nov15 00:31 GNW 0QLR:LON Novartis AG Health 208,186m Novartis presents new two year data for Cosentyx® showing no progression in joint damage in 84% of psoriatic arthritis patients
08Nov15 00:30 GNW 0QLR:LON Novartis AG Health 208,186m New two year data for Novartis' Cosentyx® show sustained response and no progression in spinal damage as shown by x-ray in up to 80% of patients with ankylosing spondylitis
04Nov15 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis nominating Elizabeth Doherty and Ton Buechner to the Board of Directors
04Nov15 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis nominating Elizabeth Doherty and Ton Buechner to the Board of Directors
29Oct15 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis Foundation and partners launch new hypertension program in Ghana
27Oct15 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance
27Oct15 06:00 GNW 0QLR:LON Novartis AG Health 208,186m Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance
23Oct15 12:25 GNW 0QLR:LON Novartis AG Health 208,186m Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis
23Oct15 12:25 GNW 0QLR:LON Novartis AG Health 208,186m Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis
21Oct15 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma
15Oct15 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Kenya first country to launch 'Novartis Access', expanding affordable treatment options against chronic diseases
10Oct15 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Novartis presents new data showing that the majority of patients are able to maintain clear or almost clear skin with Cosentyx across 3 years
08Oct15 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years
05Oct15 06:15 GNW 0QLR:LON Novartis AG Health 208,186m Alcon receives FDA Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgery
02Oct15 06:15 GNW 0QLR:LON Novartis AG Health 208,186m FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept
Date / Time Source Company % Chg
14Jul16 06:15 GNW Novartis AG 0.70%
Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
13Jul16 20:42 GNW Novartis AG 0.70%
Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases
07Jul16 06:15 GNW Novartis AG 0.70%
New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product
29Jun16 22:00 GNW Novartis AG 0.70%
Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM)
29Jun16 06:15 GNW Novartis AG 0.70%
Largest global psoriasis survey shows 84% of people face discrimination and humiliation because of their skin
28Jun16 06:15 GNW Novartis AG 0.70%
Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor
22Jun16 16:30 GNW Novartis AG 0.70%
Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology
15Jun16 06:15 GNW Novartis AG 0.70%
Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment
10Jun16 07:31 GNW Novartis AG 0.70%
Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorder
10Jun16 07:30 GNW Novartis AG 0.70%
Novartis presents data showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV)
09Jun16 06:15 GNW Novartis AG 0.70%
New data demonstrates Sandoz' etanercept and rituximab biosimilar candidates bioequivalent to originator products
08Jun16 21:30 GNW Novartis AG 0.70%
Novartis announces AMG 334 significantly reduces patients' monthly migraine days in phase II study of chronic migraine prevention
08Jun16 06:15 GNW Novartis AG 0.70%
Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016
06Jun16 19:39 GNW Novartis AG 0.70%
Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma
06Jun16 15:53 GNW Novartis AG 0.70%
Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer
04Jun16 21:00 GNW Novartis AG 0.70%
Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna®
02Jun16 06:15 GNW Novartis AG 0.70%
Novartis drug Afinitor® receives EU approval to treat certain types of advanced gastrointestinal (GI) and lung neuroendocrine tumors (NET)
25May16 06:00 GNW Novartis AG 0.70%
Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event
24May16 06:15 GNW Novartis AG 0.70%
Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency
21May16 01:01 GNW Novartis AG 0.70%
Novartis' Entresto® given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals
19May16 06:15 GNW Novartis AG 0.70%
Novartis announces investment in FortiHFy clinical program of Entresto® and heart failure
18May16 22:00 GNW Novartis AG 0.70%
Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting
18May16 06:15 GNW Novartis AG 0.70%
MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer
17May16 16:30 GNW Novartis AG 0.70%
Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis
17May16 16:30 GNW Novartis AG 0.70%
Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis
17May16 06:15 GNW Novartis AG 0.70%
Novartis Foundation and partners launch innovative hypertension program in Vietnam
15May16 18:45 GNW Novartis AG 0.70%
Major study published in NEJM confirms Novartis' Ultibro® Breezhaler® superiority over Seretide® in preventing COPD exacerbations
29Apr16 12:37 GNW Novartis AG 0.70%
Novartis drug Afinitor® recommended by CHMP for European Union approval to treat select GI and lung neuroendocrine tumors
28Apr16 06:15 GNW Novartis AG 0.70%
Novartis celebrates 20th annual Community Partnership Day with more than 27,500 associates volunteering in their local communities
27Apr16 06:15 GNW Novartis AG 0.70%
Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes
20Apr16 17:00 GNW Novartis AG 0.70%
Novartis drug Afinitor® significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex
08Apr16 06:15 GNW Novartis AG 0.70%
Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit's® nephrology indication
07Apr16 06:15 GNW Novartis AG 0.70%
Novartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year and above with chronic ITP
02Apr16 16:00 GNW Novartis AG 0.70%
New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless...
31Mar16 06:00 GNW Novartis AG 0.70%
Novartis publishes updated 2015 segment financials reflecting new division structure
05Mar16 17:00 GNW Novartis AG 0.70%
Novartis' Cosentyx superior to Stelara in delivering long-lasting skin clearance (PASI 90) for psoriasis patients at 52 weeks
26Feb16 19:44 GNW Novartis AG 0.70%
FDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET)
23Feb16 12:20 GNW Novartis AG 0.70%
Novartis shareholders approve all resolutions proposed by Board of Directors
19Feb16 06:15 GNW Novartis AG 0.70%
Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)
18Feb16 06:00 GNW Novartis AG 0.70%
Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.
12Feb16 06:00 GNW Novartis AG 0.70%
Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer's biosimilar infliximab in EEA
11Feb16 06:15 GNW Novartis AG 0.70%
Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
31Jan16 06:30 GNW Novartis AG 0.70%
Novartis Foundation commemorates World Leprosy Day with its continued efforts to go the last mile toward elimination
27Jan16 06:00 GNW Novartis AG 0.70%
Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations
27Jan16 06:00 GNW Novartis AG 0.70%
Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations
17Jan16 21:00 GNW Novartis AG 0.70%
Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US
15Jan16 22:27 GNW Novartis AG 0.70%
Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US
11Jan16 06:15 GNW Novartis AG 0.70%
Novartis continues to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface Oncology
05Jan16 22:00 GNW Novartis AG 0.70%
Novartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPD
23Dec15 22:00 GNW Novartis AG 0.70%
Novartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patients
09Dec15 06:15 GNW Novartis AG 0.70%
300 million child-friendly antimalarial treatments supplied without profit by Novartis
08Dec15 06:15 GNW Novartis AG 0.70%
Sandoz advances its biosimilars program with European Medicines Agency (EMA) acceptance of regulatory submission for biosimilar etanercept
07Dec15 19:45 GNW Novartis AG 0.70%
Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL
07Dec15 15:45 GNW Novartis AG 0.70%
Phase III data shows Sandoz' proposed biosimilar pegfilgrastim has similar safety and efficacy as the reference product
06Dec15 16:00 GNW Novartis AG 0.70%
Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations
06Dec15 12:30 GNW Novartis AG 0.70%
Novartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma
05Dec15 14:30 GNW Novartis AG 0.70%
Novartis announces Phase III studies of Jakavi show disease improvement in patients with myelofibrosis and polycythemia vera
02Dec15 06:15 GNW Novartis AG 0.70%
Novartis presents new data on targeted combination therapy at SABCS reinforcing commitment to breast cancer patients
30Nov15 06:15 GNW Novartis AG 0.70%
Novartis highlights clinical advances at ASH 2015, underscoring leadership in hematology research
24Nov15 06:15 GNW Novartis AG 0.70%
Novartis' heart failure medicine Entresto(TM) receives EU approval
23Nov15 06:15 GNW Novartis AG 0.70%
Novartis receives two landmark European approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis
18Nov15 06:15 GNW Novartis AG 0.70%
Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA
17Nov15 06:15 GNW Novartis AG 0.70%
FLAME study shows superiority of Novartis' Ultibro® Breezhaler® over Seretide® in reducing COPD exacerbations
15Nov15 17:00 GNW Novartis AG 0.70%
Alcon introduces Contoura Vision as first personalized LASIK procedure at American Academy of Ophthalmology Annual Meeting
08Nov15 00:31 GNW Novartis AG 0.70%
Novartis presents new two year data for Cosentyx® showing no progression in joint damage in 84% of psoriatic arthritis patients
08Nov15 00:30 GNW Novartis AG 0.70%
New two year data for Novartis' Cosentyx® show sustained response and no progression in spinal damage as shown by x-ray in up to 80% of patients with ankylosing spondylitis
04Nov15 06:00 GNW Novartis AG 0.70%
Novartis nominating Elizabeth Doherty and Ton Buechner to the Board of Directors
04Nov15 06:00 GNW Novartis AG 0.70%
Novartis nominating Elizabeth Doherty and Ton Buechner to the Board of Directors
29Oct15 06:15 GNW Novartis AG 0.70%
Novartis Foundation and partners launch new hypertension program in Ghana
27Oct15 06:00 GNW Novartis AG 0.70%
Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance
27Oct15 06:00 GNW Novartis AG 0.70%
Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance
23Oct15 12:25 GNW Novartis AG 0.70%
Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis
23Oct15 12:25 GNW Novartis AG 0.70%
Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis
21Oct15 06:15 GNW Novartis AG 0.70%
Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma
15Oct15 06:15 GNW Novartis AG 0.70%
Kenya first country to launch 'Novartis Access', expanding affordable treatment options against chronic diseases
10Oct15 06:15 GNW Novartis AG 0.70%
Novartis presents new data showing that the majority of patients are able to maintain clear or almost clear skin with Cosentyx across 3 years
08Oct15 06:15 GNW Novartis AG 0.70%
Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years
05Oct15 06:15 GNW Novartis AG 0.70%
Alcon receives FDA Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgery
02Oct15 06:15 GNW Novartis AG 0.70%
FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept
Date / Time Company % Chg
14Jul16 06:15 Novartis AG 0.70%
Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
13Jul16 20:42 Novartis AG 0.70%
Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases
07Jul16 06:15 Novartis AG 0.70%
New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product
29Jun16 22:00 Novartis AG 0.70%
Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM)
29Jun16 06:15 Novartis AG 0.70%
Largest global psoriasis survey shows 84% of people face discrimination and humiliation because of their skin
28Jun16 06:15 Novartis AG 0.70%
Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor
22Jun16 16:30 Novartis AG 0.70%
Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology
15Jun16 06:15 Novartis AG 0.70%
Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment
10Jun16 07:31 Novartis AG 0.70%
Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorder
10Jun16 07:30 Novartis AG 0.70%
Novartis presents data showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV)
09Jun16 06:15 Novartis AG 0.70%
New data demonstrates Sandoz' etanercept and rituximab biosimilar candidates bioequivalent to originator products
08Jun16 21:30 Novartis AG 0.70%
Novartis announces AMG 334 significantly reduces patients' monthly migraine days in phase II study of chronic migraine prevention
08Jun16 06:15 Novartis AG 0.70%
Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016
06Jun16 19:39 Novartis AG 0.70%
Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma
06Jun16 15:53 Novartis AG 0.70%
Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer
04Jun16 21:00 Novartis AG 0.70%
Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna®
02Jun16 06:15 Novartis AG 0.70%
Novartis drug Afinitor® receives EU approval to treat certain types of advanced gastrointestinal (GI) and lung neuroendocrine tumors (NET)
25May16 06:00 Novartis AG 0.70%
Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event
24May16 06:15 Novartis AG 0.70%
Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency
21May16 01:01 Novartis AG 0.70%
Novartis' Entresto® given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals
19May16 06:15 Novartis AG 0.70%
Novartis announces investment in FortiHFy clinical program of Entresto® and heart failure
18May16 22:00 Novartis AG 0.70%
Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting
18May16 06:15 Novartis AG 0.70%
MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer
17May16 16:30 Novartis AG 0.70%
Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis
17May16 16:30 Novartis AG 0.70%
Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis
17May16 06:15 Novartis AG 0.70%
Novartis Foundation and partners launch innovative hypertension program in Vietnam
15May16 18:45 Novartis AG 0.70%
Major study published in NEJM confirms Novartis' Ultibro® Breezhaler® superiority over Seretide® in preventing COPD exacerbations
29Apr16 12:37 Novartis AG 0.70%
Novartis drug Afinitor® recommended by CHMP for European Union approval to treat select GI and lung neuroendocrine tumors
28Apr16 06:15 Novartis AG 0.70%
Novartis celebrates 20th annual Community Partnership Day with more than 27,500 associates volunteering in their local communities
27Apr16 06:15 Novartis AG 0.70%
Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes
20Apr16 17:00 Novartis AG 0.70%
Novartis drug Afinitor® significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex
08Apr16 06:15 Novartis AG 0.70%
Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit's® nephrology indication
07Apr16 06:15 Novartis AG 0.70%
Novartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year and above with chronic ITP
02Apr16 16:00 Novartis AG 0.70%
New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless...
31Mar16 06:00 Novartis AG 0.70%
Novartis publishes updated 2015 segment financials reflecting new division structure
05Mar16 17:00 Novartis AG 0.70%
Novartis' Cosentyx superior to Stelara in delivering long-lasting skin clearance (PASI 90) for psoriasis patients at 52 weeks
26Feb16 19:44 Novartis AG 0.70%
FDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET)
23Feb16 12:20 Novartis AG 0.70%
Novartis shareholders approve all resolutions proposed by Board of Directors
19Feb16 06:15 Novartis AG 0.70%
Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)
18Feb16 06:00 Novartis AG 0.70%
Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.
12Feb16 06:00 Novartis AG 0.70%
Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer's biosimilar infliximab in EEA
11Feb16 06:15 Novartis AG 0.70%
Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
31Jan16 06:30 Novartis AG 0.70%
Novartis Foundation commemorates World Leprosy Day with its continued efforts to go the last mile toward elimination
27Jan16 06:00 Novartis AG 0.70%
Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations
27Jan16 06:00 Novartis AG 0.70%
Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations
17Jan16 21:00 Novartis AG 0.70%
Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US
15Jan16 22:27 Novartis AG 0.70%
Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US
11Jan16 06:15 Novartis AG 0.70%
Novartis continues to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface Oncology
05Jan16 22:00 Novartis AG 0.70%
Novartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPD
23Dec15 22:00 Novartis AG 0.70%
Novartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patients
09Dec15 06:15 Novartis AG 0.70%
300 million child-friendly antimalarial treatments supplied without profit by Novartis
08Dec15 06:15 Novartis AG 0.70%
Sandoz advances its biosimilars program with European Medicines Agency (EMA) acceptance of regulatory submission for biosimilar etanercept
07Dec15 19:45 Novartis AG 0.70%
Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL
07Dec15 15:45 Novartis AG 0.70%
Phase III data shows Sandoz' proposed biosimilar pegfilgrastim has similar safety and efficacy as the reference product
06Dec15 16:00 Novartis AG 0.70%
Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations
06Dec15 12:30 Novartis AG 0.70%
Novartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma
05Dec15 14:30 Novartis AG 0.70%
Novartis announces Phase III studies of Jakavi show disease improvement in patients with myelofibrosis and polycythemia vera
02Dec15 06:15 Novartis AG 0.70%
Novartis presents new data on targeted combination therapy at SABCS reinforcing commitment to breast cancer patients
30Nov15 06:15 Novartis AG 0.70%
Novartis highlights clinical advances at ASH 2015, underscoring leadership in hematology research
24Nov15 06:15 Novartis AG 0.70%
Novartis' heart failure medicine Entresto(TM) receives EU approval
23Nov15 06:15 Novartis AG 0.70%
Novartis receives two landmark European approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis
18Nov15 06:15 Novartis AG 0.70%
Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA
17Nov15 06:15 Novartis AG 0.70%
FLAME study shows superiority of Novartis' Ultibro® Breezhaler® over Seretide® in reducing COPD exacerbations
15Nov15 17:00 Novartis AG 0.70%
Alcon introduces Contoura Vision as first personalized LASIK procedure at American Academy of Ophthalmology Annual Meeting
08Nov15 00:31 Novartis AG 0.70%
Novartis presents new two year data for Cosentyx® showing no progression in joint damage in 84% of psoriatic arthritis patients
08Nov15 00:30 Novartis AG 0.70%
New two year data for Novartis' Cosentyx® show sustained response and no progression in spinal damage as shown by x-ray in up to 80% of patients with ankylosing spondylitis
04Nov15 06:00 Novartis AG 0.70%
Novartis nominating Elizabeth Doherty and Ton Buechner to the Board of Directors
04Nov15 06:00 Novartis AG 0.70%
Novartis nominating Elizabeth Doherty and Ton Buechner to the Board of Directors
29Oct15 06:15 Novartis AG 0.70%
Novartis Foundation and partners launch new hypertension program in Ghana
27Oct15 06:00 Novartis AG 0.70%
Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance
27Oct15 06:00 Novartis AG 0.70%
Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance
23Oct15 12:25 Novartis AG 0.70%
Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis
23Oct15 12:25 Novartis AG 0.70%
Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis
21Oct15 06:15 Novartis AG 0.70%
Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma
15Oct15 06:15 Novartis AG 0.70%
Kenya first country to launch 'Novartis Access', expanding affordable treatment options against chronic diseases
10Oct15 06:15 Novartis AG 0.70%
Novartis presents new data showing that the majority of patients are able to maintain clear or almost clear skin with Cosentyx across 3 years
08Oct15 06:15 Novartis AG 0.70%
Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years
05Oct15 06:15 Novartis AG 0.70%
Alcon receives FDA Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgery
02Oct15 06:15 Novartis AG 0.70%
FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept